Biohaven provides update on phase 3 clinical trial evaluating troriluzole for spinocerebellar ataxia (sca)

New haven, conn. , may 23, 2022 /prnewswire/ -- biohaven pharmaceutical holding company ltd.

BHVN Ratings Summary

BHVN Quant Ranking